Quartz·2 min read·hard

FDA panel overrules its own scientists to ease access to unproven peptide injections

Cris Tolomia
AI Summary

An FDA advisory committee has voted to recommend allowing compounding pharmacies to provide access to several unproven peptide injections, including BPC-157 and TB-500. This decision comes despite opposition from the FDA's own scientists regarding the safety and efficacy of these substances.

The Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157, KPV, TB-500, and MOTS-c for compounding pharmacy access

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in